US.DHR · Danaher Corporation

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.8,
      "details": {
        "atrPct": 2.875047359040771,
        "turnoverUsdM": 1122.85882929493,
        "liquidityPoints": 0.8,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.8,
    "stopLevels": {
      "symbol": "US.DHR",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 199.5836,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2,
        "rsi_score": 3,
        "macd_score": 3,
        "volume_score": 2
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.7,
      "stop_loss_percent": 5.8,
      "take_profit_price": 232.744,
      "target_multiplier": 2.2,
      "technical_strength": 2.35,
      "take_profit_percent": 9.9
    },
    "positionPoints": 1.8,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.7217107691928648,
    "stopLossPercent": 5.750094718081542,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 69.2,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 60.2,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 9
  },
  "market": {
    "ma20": 213.411,
    "ma50": 208.3618,
    "close": 211.76,
    "prevClose": 221.55,
    "avgVolume20": 4321900,
    "volumeRatio": 1.23,
    "changePercent": -4.42
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 9,
    "details": {
      "ret_5d": -0.05367122491844312,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 9,
      "vcp_bonus": 0,
      "vol_ratio": 1.2612029279373027,
      "ret_points": 0,
      "vol_points": 4,
      "range_ratio": 2.0246694317936944,
      "volat_points": 4,
      "day_range_pct": 0.051024700180614876,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 1,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 69.2,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.8,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 56,
        "contribution": 2.8
      },
      {
        "raw": 13.2,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 66,
        "contribution": 13.2
      },
      {
        "raw": 11.2,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 74.67,
        "contribution": 11.2
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 7.4,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 74,
        "contribution": 7.4
      },
      {
        "raw": 17.6,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 58.67,
        "contribution": 17.6
      },
      {
        "raw": 6,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 60,
        "contribution": 6
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "觀望",
    "result": 60.2,
    "details": [
      "基本面分析總分: 2.8/5分",
      "資金流分析總分: 13.2/20分",
      "市場環境分析總分: 11.2/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 7.4/10分",
      "技術信號分析總分: 17.6/30分",
      "情緒分析: 6/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 2.8,
      "資金流": 13.2,
      "市場環境": 11.2,
      "情緒分析": 6,
      "技術信號": 17.6,
      "風險管理": 7.4
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.4,
          "pePoints": 0.2,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.5,
          "marginPoints": 0.4,
          "turnoverUsdM": 1122.85882929493,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.3,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "一般",
        "items": {
          "cmfPoints": 2.4,
          "mfiPoints": 4,
          "obvPoints": 4,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.DHR",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "良好",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 16.34
            }
          },
          "trend": {
            "score": 3.4,
            "details": {
              "qqq": {
                "ma20": 726.18399875,
                "ma50": 715.6645994400001,
                "name": "QQQ",
                "close": 742.030029,
                "points": 2
              },
              "spy": {
                "ma20": 765.0049978999999,
                "ma50": 763.0729976399997,
                "name": "SPY",
                "close": 763.98999,
                "points": 1.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.875047359040771,
          "atrPoints": 3,
          "cciPoints": 2.4,
          "vixPoints": 2.4,
          "marketTrendPoints": 3.4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "一般",
        "items": {
          "sentiment": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 4,
              "sentimentScoreRaw": 1.2
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 142520955,
                "url": "https://finnhub.io/api/news?id=e2604dbf0993dd1f23e0744dfaa41f51d914c805b65d90ba56ea29ffda04754b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Danaher's Biotechnology segment posts 4% sales growth, but tough comparisons and shipment timing could test its momentum.",
                "category": "company",
                "datetime": 1790775060,
                "headline": "DHR's Growth Backed by Strong Biotechnology Unit: Can It Maintain the Pace?"
              },
              {
                "id": 142365268,
                "url": "https://finnhub.io/api/news?id=26ef569c26c0428324e406a0d7f96ebc49ec6308d61250cce4ddbedcd04bb932",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Danaher has delivered a 17.4% gain over the past year, which puts a spotlight on one core issue for anyone looking at the stock today: whether the current share price can be explained by the cash flows the business is expected to generate. The 17.4% 1 year return means recent buyers have seen a clear payoff, which raises the question of how much future cash generation is already reflected in the valuation. Recent reports on areas such as label free detection and single use bioreactors...",
                "category": "company",
                "datetime": 1790198318,
                "headline": "Danaher (DHR) Stock Looks Reasonable On Label Free Detection Growth"
              },
              {
                "id": 142262611,
                "url": "https://finnhub.io/api/news?id=51e65494213bb0400c0349c58f22fe3f21acfa3eb6a430626d35ba8b5d581880",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Healthcare services and products company Cardinal Health (NYSE:CAH)’s shares are up by more than 10% year-to-date but are down by more than 8% since early September. Cramer discussed the firm’s share price performance in his morning appearance on September 15th and wondered whether the weakness was due to a rotation into AI stocks rather than […]",
                "category": "company",
                "datetime": 1789773213,
                "headline": "Cardinal Health (NYSE:CAH) Vs Danaher Corporation (NYSE:DHR) – Here’s The One Jim Cramer Said Did Better"
              },
              {
                "id": 142194207,
                "url": "https://finnhub.io/api/news?id=38af460947fe383af305d3369ca08225eaafe05679b53af6cdc7e85fa0dbde1b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Danaher (DHR) has reaffirmed its shareholder payout, with the Board approving a regular quarterly cash dividend of $0.40 per share, payable on October 30, 2026, to holders of record on September 30. The reaffirmed dividend lands at a time when Danaher’s short-term momentum has picked up. The 90-day share price return is 17.78% and the 1-year total shareholder return is 10.73%, even though the 5-year total shareholder return is down 25.46%. Compare Danaher’s mix of dividend income and recent...",
                "category": "company",
                "datetime": 1789557175,
                "headline": "Danaher (DHR) Could Be 8% Below Fair Value Following Its Dividend Reaffirmation"
              },
              {
                "id": 142165895,
                "url": "https://finnhub.io/api/news?id=4e306319d28b9c86fab6c2c9dd4c4556d7f2825f07cdf375061043fa75828a64",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "ELV vs. DHR: Which Stock Is the Better Value Option?",
                "category": "company",
                "datetime": 1789486803,
                "headline": "ELV or DHR: Which Is the Better Value Stock Right Now?"
              },
              {
                "id": 142062026,
                "url": "https://finnhub.io/api/news?id=5ae6995e7d0fa2d6935997b0603dfbe3657d8c9c875e078deaabe03fb0aaaa47",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Danaher currently trades at $204.89 per share and has shown little upside over the past six months, posting a middling return of 5%. The stock also fell short of the S&P 500’s 13.1% gain during that period.",
                "category": "company",
                "datetime": 1789050784,
                "headline": "3 Reasons DHR is Risky and 1 Stock to Buy Instead"
              },
              {
                "id": 141400483,
                "url": "https://finnhub.io/api/news?id=788eeac5eae1c87653f0c3c471fec5c126d3334a1dde16e572db5f1ced667d2d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Eagle Capital Management, an investment management company, released its second quarter 2026 investor letter. A copy of the letter can be downloaded here. In the quarter, Eagle Capital Management discussed how enthusiasm around AI capital spending has driven strong S&P 500 earnings growth while also increasing risks from elevated valuations, concentrated demand, and aggressive investment assumptions. […]",
                "category": "company",
                "datetime": 1788447282,
                "headline": "Danaher (DHR) Seen Deftly Navigating AI Integration"
              },
              {
                "id": 141396047,
                "url": "https://finnhub.io/api/news?id=4379c01f6798695029c2cfe3c133d43da7884cd56b9dda27240f98d407a68618",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Danaher stock has delivered a decline of 26.6% over the past 5 years, yet current checks suggest the shares now trade near an intrinsic value estimate while still screening expensive on traditional multiples. The result is a company with mixed long term performance and a low overall value score, but without a clear discount on most valuation yardsticks. Over 5 years, Danaher shares are down 26.6%, which may lead some investors to question whether the recent pricing now already reflects that...",
                "category": "company",
                "datetime": 1788416212,
                "headline": "Danaher (DHR) Stock Trades Near Fair Value But At An Earnings Premium"
              }
            ],
            "raw_source": [
              {
                "id": 142561523,
                "url": "https://finnhub.io/api/news?id=21e7c6c97b4fdc288ec01fde3118e7f17351046c80c29bdde18a9b184c48edba",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "DHR",
                "summary": "Get insights into the S&P500 index performance on Thursday. Explore the top gainers and losers within the S&P500 index in today's session.",
                "category": "company",
                "datetime": 1790881501,
                "headline": "What's going on in today's session: S&P500 movers"
              },
              {
                "id": 142560945,
                "url": "https://finnhub.io/api/news?id=90d9e66136ab1b04aadcf4a7b84e3f29fa93353affbaf4557234e8ff0e6fcbe2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Danaher is heading into its third-quarter earnings report in the coming weeks, and Wall Street expects modest, low-single-digit earnings growth.",
                "category": "company",
                "datetime": 1790852604,
                "headline": "What You Need to Know Ahead of Danaher’s Earnings Release"
              },
              {
                "id": 142556686,
                "url": "https://finnhub.io/api/news?id=1f0fd00804e3d9f22b5c29f58682375eb66c715ae6e46e16df0a956d0f4accfe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Danaher Corporation (NYSE: DHR) (\"Danaher\" or \"the Company\") announced that, effective today, Julie Sawyer Montgomery has assumed the roles of President and Chief Executive Officer and has joined Danaher's Board of Directors, as previously announced on August 3, 2026. Since joining the Company in 2017, Ms. Sawyer Montgomery has held roles of increasing responsibility spanning commercial operations, R&D, and business leadership. In those roles, she has built a track record of advancing innovation",
                "category": "company",
                "datetime": 1790852400,
                "headline": "Julie Sawyer Montgomery Assumes Role as Danaher President and Chief Executive Officer"
              },
              {
                "id": 142558772,
                "url": "https://finnhub.io/api/news?id=ae232b7ed2d378fae0ba6003de770f1bb3bff5f87a60885430463e05e74e5a44",
                "image": "",
                "source": "Benzinga",
                "related": "DHR",
                "summary": "Guggenheim  analyst Subbu Nambi   maintains Danaher (NYSE:DHR) with a Buy and raises the price target from $200 to $250.",
                "category": "company",
                "datetime": 1790848741,
                "headline": "Guggenheim Maintains Buy on Danaher, Raises Price Target to $250"
              },
              {
                "id": 142540765,
                "url": "https://finnhub.io/api/news?id=7d6465b472d118677c03014527a5f47cd568772afebdfde05f26b16e70df37cb",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1440523601/image_1440523601.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "DHR",
                "summary": "Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation.",
                "category": "company",
                "datetime": 1790825460,
                "headline": "The Top HealthTech Questions Landing On Our Desks"
              },
              {
                "id": 142520955,
                "url": "https://finnhub.io/api/news?id=e2604dbf0993dd1f23e0744dfaa41f51d914c805b65d90ba56ea29ffda04754b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Danaher's Biotechnology segment posts 4% sales growth, but tough comparisons and shipment timing could test its momentum.",
                "category": "company",
                "datetime": 1790775060,
                "headline": "DHR's Growth Backed by Strong Biotechnology Unit: Can It Maintain the Pace?"
              },
              {
                "id": 142517735,
                "url": "https://finnhub.io/api/news?id=45edf89433c04c5b321c1383a688488145aeca8cf802986a277c5b00b56f702a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Masimo, a Danaher company and a specialty diagnostics solutions innovator of pulse oximetry and other patient monitoring solutions, today announced that it received two honors at the 2026 Octane High Tech Awards, winning Deal of the Year and Best Technology Company Leadership Team.",
                "category": "company",
                "datetime": 1790773500,
                "headline": "Masimo Wins Two OCTANE High Tech Awards - Company Recognized for 'Deal of the Year' and 'Best Technology Leadership Team'"
              },
              {
                "id": 142471934,
                "url": "https://finnhub.io/api/news?id=eaf37d954712e7a934a5240a5c29f7a9cb8c6cf82d05acd0c66826ac0db1973d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "The maker of rings is expected to price its initial public offering after the market close on Tuesday.",
                "category": "company",
                "datetime": 1790621280,
                "headline": "Oura IPO: What to Know Ahead of This Week’s Public Debut"
              },
              {
                "id": 142471332,
                "url": "https://finnhub.io/api/news?id=21d1e28fcf0606bb5c18cf2a54da696b3b2cdbe48e977d57eb98666e978316cd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "The maker of rings is expected to price its initial public offering after the market close on Tuesday.",
                "category": "company",
                "datetime": 1790621280,
                "headline": "Oura IPO Looks to Cash In on Growing Consumer Interest in Health Data"
              },
              {
                "id": 142470289,
                "url": "https://finnhub.io/api/news?id=a7083a919d52bb2392d245f7cc8b44ce2561bdc6e2c5dccbf125b8b71a586848",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) and Danaher Corporation (NYSE:DHR) are both showing signs of stronger growth, but they are getting there in very different ways. Gilead already has momentum, which is supported by its HIV business that is expanding at a double-digit rate, with newer products contributing more and resulting in management raising its sales outlook. […]",
                "category": "company",
                "datetime": 1790621106,
                "headline": "Gilead vs. Danaher: Which Healthcare Growth Story is More Convincing?"
              },
              {
                "id": 142466438,
                "url": "https://finnhub.io/api/news?id=66293804a0b8c7e8fe8aa6ad7d20cd474e4707f7db3f1230f332a70a263edcf0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Leica Biosystems, a Danaher company (the \"Company\") and a global leader in digital and anatomic pathology solutions advancing precision cancer diagnostics, announced today that the Company has completed its acquisition of privately held StatLab Medical Products (\"StatLab\"), a leading provider of pre-analytical consumables and equipment, from Linden Capital Partners and Audax Private Equity. For patients and their care teams, precision cancer diagnostics can provide critical information about the",
                "category": "company",
                "datetime": 1790600400,
                "headline": "Leica Biosystems Completes Acquisition of StatLab to Bolster Delivery of More Precise, Timely Diagnostics for Cancer Patients"
              },
              {
                "id": 142432371,
                "url": "https://finnhub.io/api/news?id=403589f5a28b768b40e6b9e54ab5a5d2aa8836e772aecee6e6c1fa8830560d81",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "DHR",
                "summary": "Get the weekly summary of dividend changes for Dividend Champions, Contenders & Challengers, plus upcoming ex-dividend and pay dates.",
                "category": "company",
                "datetime": 1790377479,
                "headline": "Dividend Champion, Contender, And Challenger Highlights: Week September 27"
              },
              {
                "id": 142378130,
                "url": "https://finnhub.io/api/news?id=a6a2698a12e235b7483efb3690526ce2fedb211b659108492c6bf866419ee73a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Opportunities center on automated, standardized TDM kits integrated with AI dosing tools for antimicrobial stewardship, transplant care and precision medicine, especially in Asia-Pacific.Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- \"TDM Reagent Kit Market - Global Forecast 2026-2032\" has been added to ResearchAndMarkets.com's offering. This market research report examines the global TDM Reagent Kit Market, projected to reach USD 2.87 billion in 2026 and grow at a CAGR of 15.84% to USD 6.96 billion",
                "category": "company",
                "datetime": 1790254740,
                "headline": "TDM Reagent Kit Market Forecasts Growth from $2.87B (2026) to $6.96B by 2032, Profiling Abbott, Roche, Danaher, Siemens Healthineers & Thermo Fisher"
              },
              {
                "id": 142373168,
                "url": "https://finnhub.io/api/news?id=7a37969885fd72539f9794fa81246294a8d812436cceaac8ff4432f5c912e606",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1372801150/image_1372801150.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "DHR",
                "summary": "Danaher (DHR) stays a hold: modest core growth and higher leverage after the Masimo acquisition limit upside despite synergies.",
                "category": "company",
                "datetime": 1790218159,
                "headline": "Danaher Isn't Anything Special, Even After Absorbing Masimo"
              },
              {
                "id": 142365268,
                "url": "https://finnhub.io/api/news?id=26ef569c26c0428324e406a0d7f96ebc49ec6308d61250cce4ddbedcd04bb932",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Danaher has delivered a 17.4% gain over the past year, which puts a spotlight on one core issue for anyone looking at the stock today: whether the current share price can be explained by the cash flows the business is expected to generate. The 17.4% 1 year return means recent buyers have seen a clear payoff, which raises the question of how much future cash generation is already reflected in the valuation. Recent reports on areas such as label free detection and single use bioreactors...",
                "category": "company",
                "datetime": 1790198318,
                "headline": "Danaher (DHR) Stock Looks Reasonable On Label Free Detection Growth"
              },
              {
                "id": 142357836,
                "url": "https://finnhub.io/api/news?id=4990e7052d529b75225f28fade94aabfadfa881cb32171a4d7e758ae349000f5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "ROCKVILLE, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it has appointed Sidharth Kapileshwar as Chief Corporate Development Officer. \"Sidharth has a proven track record of building and scaling corporate development functions inside some of the largest healthcare companies in the",
                "category": "company",
                "datetime": 1790165100,
                "headline": "MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer"
              },
              {
                "id": 142356666,
                "url": "https://finnhub.io/api/news?id=c58aec494eadad86cbe6c488959571345dabf20958cb3b3e229386f3c28a347c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Biologics, stricter purity rules and flexible manufacturing are driving demand for single-use, automated and continuous filtration, advanced membranes and sustainable systems.Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- \"Pharmaceutical Filtration - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering.The global market for Pharmaceutical Filtration was estimated at US$8.0 Billion in 2025 and is projected to reach US$23.4 Billion by 2032, growing at a CAGR of 16.7% f",
                "category": "company",
                "datetime": 1790157360,
                "headline": "Global Pharmaceutical Filtration Report: Biologics Manufacturing Shifts as Danaher, Merck KGaA, Sartorius, 3M and Thermo Fisher Reshape the Market"
              },
              {
                "id": 142356138,
                "url": "https://finnhub.io/api/news?id=27c59eb4e1fc7a6828660b3c7958466dbdfe4cec311a3be419231ad4e6952162",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Bioreactors Market Gains Momentum as Single-Use Systems, Automation and Advanced Therapies Reshape BiomanufacturingDublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- \"Bioreactors Market Opportunity, Growth Drivers, Industry Trend Analysis and Forecast 2026-2035\" has been added to ResearchAndMarkets.com's offering. Global Bioreactors Market to Reach USD 38.9 Billion by 2035 as Advanced Biomanufacturing Expands The global bioreactors market was valued at USD 13.8 billion in 2025 and is projected to reach",
                "category": "company",
                "datetime": 1790154060,
                "headline": "Bioreactors Market Outlook 2026-2035 - Featuring Profiles of 3 Leading Companies: Sartorius, Thermo Fisher Scientific, and Danaher"
              },
              {
                "id": 142343074,
                "url": "https://finnhub.io/api/news?id=024dd3a234c7eca03501f0827dacf6c26181f424e91476b9727a17b6cb9e67cf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2026 on Wednesday, October 21, 2026 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations.",
                "category": "company",
                "datetime": 1790108100,
                "headline": "Danaher Schedules Third Quarter 2026 Earnings Conference Call"
              },
              {
                "id": 142340992,
                "url": "https://finnhub.io/api/news?id=7f9451e056dd0c45a4304b88f0f9ccd9306f02bc7a8be5192dacae80dd8a134d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Stock Market Today: The Dow Jones index was lower after President Trump threatened Iran at the UN. Apple stock is near a buy point.",
                "category": "company",
                "datetime": 1790105129,
                "headline": "Stock Market Today: Dow Skids As Trump Threatens Iran; Medical Diagnostics Plays Swoon (Live Coverage)"
              },
              {
                "id": 142328474,
                "url": "https://finnhub.io/api/news?id=85efb7d8043da2785c44589fe07e464369b52343ea3a62c863b956ea862cb220",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "AI-enabled, microfluidic label-free detection is expanding in drug discovery, early diagnostics, food safety and environmental testing, driven by efficient, non-invasive, sustainable workflows.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- \"Label-Free Detection - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering.The global market for Label-Free Detection was valued at US$553 Million in 2024 and is projected to reach US$847 Million by 2030, growing at a CAGR of 7.4",
                "category": "company",
                "datetime": 1790065560,
                "headline": "Capitalize on the Label-Free Detection Market Shift: Track How Danaher, Sartorius, Agilent, Bruker and Revvity Are Disrupting R&D ROI and Reshaping Global Revenue Through 2030"
              },
              {
                "id": 142328475,
                "url": "https://finnhub.io/api/news?id=b8f5142c375749dcd86f165528c6ac8eb46172a6658a4d6afd34853bb9496e20",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Demand is rising for single-use, automated and real-time aseptic sampling as biopharma and food producers prioritize contamination control, continuous manufacturing and compliance.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- \"Aseptic Sampling - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering.The global market for Aseptic Sampling was estimated at US$867.4 Million in 2025 and is projected to reach US$1.3 Billion by 2032, growing at a CAGR of 6.3% from 2025 to 2",
                "category": "company",
                "datetime": 1790065440,
                "headline": "Capitalize on the Aseptic Sampling Shift: Benchmark Merck KGaA, Sartorius, Thermo Fisher Scientific, Danaher and GEA to Secure Bioprocessing ROI Across the Forecast Period"
              },
              {
                "id": 142328487,
                "url": "https://finnhub.io/api/news?id=293df837bbb17c71cf269b411ac0010b830920bae67dc70e20edcee04009550a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "High-content screening is advancing drug discovery and personalized medicine, driven by 3D models, advanced imaging and automated analytics, with opportunities in cancer research and organoids.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- \"High Content Screening (HCS) - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering.The global market for High Content Screening (HCS) was valued at US$1.3 Billion in 2024 and is projected to reach US$2.2 Billion by 2030, growing",
                "category": "company",
                "datetime": 1790065140,
                "headline": "Capitalize on High Content Screening Disruption: Decode How Thermo Fisher Scientific, Danaher, Revvity, and Yokogawa Are Reshaping Global R&D ROI and Revenue"
              },
              {
                "id": 142262611,
                "url": "https://finnhub.io/api/news?id=51e65494213bb0400c0349c58f22fe3f21acfa3eb6a430626d35ba8b5d581880",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Healthcare services and products company Cardinal Health (NYSE:CAH)’s shares are up by more than 10% year-to-date but are down by more than 8% since early September. Cramer discussed the firm’s share price performance in his morning appearance on September 15th and wondered whether the weakness was due to a rotation into AI stocks rather than […]",
                "category": "company",
                "datetime": 1789773213,
                "headline": "Cardinal Health (NYSE:CAH) Vs Danaher Corporation (NYSE:DHR) – Here’s The One Jim Cramer Said Did Better"
              },
              {
                "id": 142259858,
                "url": "https://finnhub.io/api/news?id=b3a93c4bd18a6ac2a3e42e5fb8be71948ca4fff5d25aeb220a598ff9295ff662",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.",
                "category": "company",
                "datetime": 1789740520,
                "headline": "1 Mid-Cap Stock on Our Buy List and 2 We Avoid"
              },
              {
                "id": 142253117,
                "url": "https://finnhub.io/api/news?id=e11028fe46d2f48c6ef48e72b060b54606b0ee35c8994be445e30b364af77ec5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.",
                "category": "company",
                "datetime": 1789727560,
                "headline": "2 Unpopular Stocks That Should Get More Attention and 1 We Question"
              },
              {
                "id": 142225270,
                "url": "https://finnhub.io/api/news?id=93b6eb6935bb9fb92458d42f99af72bb0cbbf612e4e8677b8e888d9df4d3223e",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "DHR",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often",
                "category": "company",
                "datetime": 1789565721,
                "headline": "10 Health Care Stocks Whale Activity In Today’s Session"
              },
              {
                "id": 142194207,
                "url": "https://finnhub.io/api/news?id=38af460947fe383af305d3369ca08225eaafe05679b53af6cdc7e85fa0dbde1b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Danaher (DHR) has reaffirmed its shareholder payout, with the Board approving a regular quarterly cash dividend of $0.40 per share, payable on October 30, 2026, to holders of record on September 30. The reaffirmed dividend lands at a time when Danaher’s short-term momentum has picked up. The 90-day share price return is 17.78% and the 1-year total shareholder return is 10.73%, even though the 5-year total shareholder return is down 25.46%. Compare Danaher’s mix of dividend income and recent...",
                "category": "company",
                "datetime": 1789557175,
                "headline": "Danaher (DHR) Could Be 8% Below Fair Value Following Its Dividend Reaffirmation"
              },
              {
                "id": 142186172,
                "url": "https://finnhub.io/api/news?id=cdc41b2262748c311db502b213c10c0530f1ccf9237007ee212d21f9e6a81cd5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "The global point-of-care diagnostics market is projected to grow from USD 20.63 billion in 2026 to USD 31.46 billion by 2031, at an 8.8% CAGR. Growth is driven by demand for rapid, accurate and decentralized testing, alongside advances in molecular diagnostics, microfluidics, multiplex assays and portable analyzers. Biochemistry holds the largest technology share, while molecular diagnostics and infectious disease testing are set for strong growth. Clinical laboratories lead by end user, and Nor",
                "category": "company",
                "datetime": 1789549500,
                "headline": "Point of Care Diagnostics Market Forecasts Growth from $20.63B (2026) to $31.46B by 2031, Profiling QuidelOrtho, Sysmex, HemoCue, Trinity Biotech & 15 Other Key Players"
              },
              {
                "id": 142172841,
                "url": "https://finnhub.io/api/news?id=61b3769a5ad1c3e6317c10c4a8cabfdb13b7ba01434148202a0b9fb81e80a31a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Donaldson (DCI) has gained 9.1% over the past twelve months and still trades about 20% below its 52-week high. The filtration company behind those numbers sells replacement parts into equipment already in service, and the cash from that stream has been steadily shrinking its share count. The shrinking count is the case for buying the pullback. It is also the part that goes quiet in fiscal 2027.",
                "category": "company",
                "datetime": 1789521554,
                "headline": "Should You Buy Donaldson Stock While Its Share Count Stops Shrinking?"
              },
              {
                "id": 142168643,
                "url": "https://finnhub.io/api/news?id=454593377a3a4b30c8b1ad0631e8a556b436eb9aa98c74338cb26b286a9a686f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.40 per share of its common stock, payable on October 30, 2026 to holders of record on September 30, 2026.",
                "category": "company",
                "datetime": 1789503300,
                "headline": "Danaher Announces Quarterly Dividend"
              },
              {
                "id": 142165895,
                "url": "https://finnhub.io/api/news?id=4e306319d28b9c86fab6c2c9dd4c4556d7f2825f07cdf375061043fa75828a64",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "ELV vs. DHR: Which Stock Is the Better Value Option?",
                "category": "company",
                "datetime": 1789486803,
                "headline": "ELV or DHR: Which Is the Better Value Stock Right Now?"
              },
              {
                "id": 142165726,
                "url": "https://finnhub.io/api/news?id=8299b557964e748613961fe998a9e87486a61281530a1d32235975f64fa612d6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Opportunities center on AI-enabled imaging, lab automation, advanced 3D and patient-derived cell models, CRO partnerships, and expanding global life sciences research.Dublin, Sept. 15, 2026 (GLOBE NEWSWIRE) -- \"High Content Screening Market - Global Forecast 2026-2032\" has been added to ResearchAndMarkets.com's offering. This market research report examines the global High Content Screening Market, projected to reach USD 3.37 billion in 2026 and USD 6.58 billion by 2032, representing a CAGR of 1",
                "category": "company",
                "datetime": 1789483200,
                "headline": "High Content Screening Market Forecasts Growth from $3.37B (2026) to $6.58B by 2032, Profiling Thermo Fisher, Danaher, GE HealthCare & 27 Other Key Players"
              },
              {
                "id": 142157641,
                "url": "https://finnhub.io/api/news?id=2c7aae65c2f01b8c239dbfbc3b6bd20e7655d21febf3d49db262fad80660ccab",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "The global single-use bioreactors market is forecast to grow from USD 5.43 billion in 2026 to USD 9.58 billion by 2031, at a 12.0% CAGR. Growth is driven by biologics, biosimilars, vaccine manufacturing, CDMO outsourcing, and flexible bioprocessing. Bioproduction and monoclonal antibodies led the market in 2025, while Asia Pacific is expected to grow fastest through 2031. Key players include Sartorius, Danaher, Thermo Fisher Scientific, and Merck KGaA.Dublin, Sept. 15, 2026 (GLOBE NEWSWIRE) -- \"",
                "category": "company",
                "datetime": 1789462500,
                "headline": "Single-Use Bioreactors Market by Product, Type, Cell Type, Molecule, Process Mode, Application, Competition, Region - Global Forecast to 2031"
              },
              {
                "id": 142067554,
                "url": "https://finnhub.io/api/news?id=4b5cfa3a17d5c7ca5796ad812ea083253e3ac401cd45a8f94e14414a7426fc81",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/186805810/image_186805810.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "DHR",
                "summary": "Third Point’s Q2 2026 13F: portfolio doubled to $4.68B as WBD becomes top holding; new buys include Keysight, Block; exits Meta/Nvidia. See more here.",
                "category": "company",
                "datetime": 1789072767,
                "headline": "Tracking Dan Loeb's Third Point Portfolio - Q2 2026 Update"
              },
              {
                "id": 142062026,
                "url": "https://finnhub.io/api/news?id=5ae6995e7d0fa2d6935997b0603dfbe3657d8c9c875e078deaabe03fb0aaaa47",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Danaher currently trades at $204.89 per share and has shown little upside over the past six months, posting a middling return of 5%. The stock also fell short of the S&P 500’s 13.1% gain during that period.",
                "category": "company",
                "datetime": 1789050784,
                "headline": "3 Reasons DHR is Risky and 1 Stock to Buy Instead"
              },
              {
                "id": 142027414,
                "url": "https://finnhub.io/api/news?id=f0d2402130489b10f71517e049005a0a2b7299da1fbec991faf3476fc4808d3f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Thermo Fisher Scientific (TMO) and Danaher (DHR) are likely to return to mid-single-digit organic re",
                "category": "company",
                "datetime": 1788976546,
                "headline": "Thermo Fisher, Danaher Could Log Mid-Single-Digit Organic Revenue Growth in 2027, UBS Says"
              },
              {
                "id": 141953788,
                "url": "https://finnhub.io/api/news?id=dddaf795f9e9e73cddfc19f508575f5637f8aab85261019519c504a89f3a4189",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "A gene sequencing leader is on a powerful run fueled by real business quality, forcing investors to decide if the engine has more power than the price tag already reflects.",
                "category": "company",
                "datetime": 1788896244,
                "headline": "ILMN Stock Keeps Climbing. Should You Climb On?"
              },
              {
                "id": 141950366,
                "url": "https://finnhub.io/api/news?id=9ffbefa46ae6a3e4ca32751051e8d41fdf4e5c7ea74772461a6e2e856ea0ded6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "500-Page Report Spans 450 Data Tables Across Product, Species, Host Cell, and Application Segments as Human Recombinant Proteins Lead Demand Research Use Recombinant Protein Market Research Use Recombinant Protein Market Dublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The \"Research Use Recombinant Protein Market by Product, Product Formulation, Species, Host Cell, Application, End User, Region - Global Forecast to 2031\" has been added to ResearchAndMarkets.com's offering. Research Use Recombinant Pro",
                "category": "company",
                "datetime": 1788878940,
                "headline": "Research Use Recombinant Protein Market Report Now Available — Forecasts Market Growth from $1.11B (2026) to $1.55B by 2031, Profiling Thermo Fisher, Bio-Techne, Merck KGaA, Danaher, Revvity, and Others"
              },
              {
                "id": 141913510,
                "url": "https://finnhub.io/api/news?id=93030636154aeb4442631985be95aeeb84233bfcad77a6092698cf29fcc0784c",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2238217382/image_2238217382.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "DHR",
                "summary": "Pharmaceuticals are rebounding as U.S. drug pricing clarity emerges, shifting focus to patent expirations and innovation-driven differentiation.",
                "category": "company",
                "datetime": 1788848276,
                "headline": "Health Care's Next Act: Tailwinds Emerging Across R&D Cycle"
              },
              {
                "id": 141425678,
                "url": "https://finnhub.io/api/news?id=f21a96053f253b59f417bd859feef95f766270d2e42bafa9937419d4bfaae0dc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Revvity's raised 2026 outlook, Diagnostics growth and stronger cash flow brighten the setup, but premium valuation and software risks call for selectivity.",
                "category": "company",
                "datetime": 1788526140,
                "headline": "Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich?"
              },
              {
                "id": 141420277,
                "url": "https://finnhub.io/api/news?id=8dff4283f6da452e92865d7101fd6ffa7f2bdc63d99febe33fac804fc18f8255",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "The global multiplex assays market is projected to grow from US$6.8 billion in 2025 to US$12.4 billion by 2030, at a 12.8% CAGR. North America leads with a 34% share, while Asia Pacific is the fastest-growing region at 15.5%; India is forecast to expand at 16.9%. Consumables account for 68% of sales and protein multiplex assays hold 42%. Growth is driven by precision medicine, companion diagnostics, biomarker R&D, molecular diagnostics and laboratory automation. Key players include Thermo Fisher",
                "category": "company",
                "datetime": 1788518880,
                "headline": "Global Multiplex Assays Market 2026 Edition -  Consumables Dominate Multiplex Assays with 68% Market Share"
              },
              {
                "id": 141400482,
                "url": "https://finnhub.io/api/news?id=f1c6c41eb50093b1d2c2422f9e74ee96a6d8581a6cf8040e00345344fac103b4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Pediatrix Medical Group (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788449418,
                "headline": "Pediatrix Medical Group (MD) Up 3.4% Since Last Earnings Report: Can It Continue?"
              },
              {
                "id": 141400483,
                "url": "https://finnhub.io/api/news?id=788eeac5eae1c87653f0c3c471fec5c126d3334a1dde16e572db5f1ced667d2d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Eagle Capital Management, an investment management company, released its second quarter 2026 investor letter. A copy of the letter can be downloaded here. In the quarter, Eagle Capital Management discussed how enthusiasm around AI capital spending has driven strong S&P 500 earnings growth while also increasing risks from elevated valuations, concentrated demand, and aggressive investment assumptions. […]",
                "category": "company",
                "datetime": 1788447282,
                "headline": "Danaher (DHR) Seen Deftly Navigating AI Integration"
              },
              {
                "id": 141403192,
                "url": "https://finnhub.io/api/news?id=222861cbe182e09bd124e5448a1086f89de7650eb4bc2e208436fb5e5363a845",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2193840462/image_2193840462.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "DHR",
                "summary": "As legacy pharmaceutical models face structural challenges, targeting the underlying technology enablers of next-generation care offers a compelling approach for healthcare investors.",
                "category": "company",
                "datetime": 1788444600,
                "headline": "Why Moderna's Cancer Vaccine Matters To Investors"
              },
              {
                "id": 141398213,
                "url": "https://finnhub.io/api/news?id=830324349e2e788af520b7f959b46403f4a04ca93752f30416c2c4d834b3de10",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Genedata, the leading provider of enterprise software for biopharmaceutical R&D, today announced an expanded collaboration with Abcam, a global provider of validated antibodies and assay solutions. By deploying Genedata Biologics® across Abcam's global R&D organization, the two Danaher companies are working together to strengthen antibody development capabilities, unlock the value of scientific data, and accelerate AI-enabled innovation.",
                "category": "company",
                "datetime": 1788442200,
                "headline": "Abcam and Genedata Collaborate to Accelerate AI-Driven Antibody Development at Global Scale"
              },
              {
                "id": 141396047,
                "url": "https://finnhub.io/api/news?id=4379c01f6798695029c2cfe3c133d43da7884cd56b9dda27240f98d407a68618",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Danaher stock has delivered a decline of 26.6% over the past 5 years, yet current checks suggest the shares now trade near an intrinsic value estimate while still screening expensive on traditional multiples. The result is a company with mixed long term performance and a low overall value score, but without a clear discount on most valuation yardsticks. Over 5 years, Danaher shares are down 26.6%, which may lead some investors to question whether the recent pricing now already reflects that...",
                "category": "company",
                "datetime": 1788416212,
                "headline": "Danaher (DHR) Stock Trades Near Fair Value But At An Earnings Premium"
              },
              {
                "id": 141361110,
                "url": "https://finnhub.io/api/news?id=d5ff30661b36ade78c981291fb8200bfdc2b3593b5b7a0f879ffc1bdf536d503",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DHR",
                "summary": "Merck KGaA (NYSE:MRK) shares rose 1. 7% to €141.",
                "category": "company",
                "datetime": 1788263097,
                "headline": "Merck KGaA shares rise 1.7% after HSBC upgrades stock to Buy"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 4,
            "recomputed_at_score": true,
            "sentiment_score_raw": 1.2,
            "source_article_count": 48,
            "discarded_article_count": 40
          },
          "sentimentPoints": 6
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 17.6,
        "grade": "較差",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 0.9,
          "macdPoints": 4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 0.9,
            "vcp_reason": "站上MA50；升放量(近10日5日)；Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 6,
              "vol_ref": 3982306.6666666665,
              "down_days": 3,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 5261410,
              "avg_vol_20": 4204325,
              "avg_vol_30": 3982306.6666666665,
              "range_pct_10": 0.10242728099864379,
              "range_pct_20": 0.13831698802025813,
              "range_pct_30": 0.13831698802025813,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": false,
              "contraction_ok": false,
              "down_shrink_ok": false,
              "up_expand_days": 5,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 1.321196592929391,
              "dist_to_20d_high": 0.07277349154917247,
              "down_shrink_days": 1,
              "breakout_level_20d": 228.38,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.7405256755854323
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 1.2
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.8,
            "details": {
              "atrPct": 2.875047359040771,
              "turnoverUsdM": 1122.85882929493,
              "liquidityPoints": 0.8,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.8,
          "stopLevels": {
            "symbol": "US.DHR",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 199.5836,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2,
              "rsi_score": 3,
              "macd_score": 3,
              "volume_score": 2
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.7,
            "stop_loss_percent": 5.8,
            "take_profit_price": 232.744,
            "target_multiplier": 2.2,
            "technical_strength": 2.35,
            "take_profit_percent": 9.9
          },
          "positionPoints": 1.8,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.7217107691928648,
          "stopLossPercent": 5.750094718081542,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 85.71,
    "atr": {
      "atr": 6.0882,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.88
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "平衡",
      "score": 6,
      "value": 17.73
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "輕微流入",
      "score": 6,
      "value": 0.1817
    },
    "kdj": {
      "d": 76.04,
      "j": 22.38,
      "k": 58.15,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "強資金流入",
      "score": 10,
      "value": 78.94
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": 2163693,
      "recentSlope": 1458889.3,
      "previousSlope": -1488170
    },
    "rsi": 62.59,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 228.38,
      "position": "SAR喺價上",
      "distancePct": 7.85,
      "previousTrend": "上升"
    },
    "ma50": 208.3618,
    "macd": {
      "macd": 3.8732387965781356,
      "trend": "強烈看漲",
      "signal": 3.677905139456204,
      "histogram": 0.19533365712193174
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 214.1201,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "有量",
      "ratio": 1.23,
      "score": 6,
      "avgVolume": 4321900,
      "currentVolume": 5302507
    },
    "derived": {
      "ma20": 213.411,
      "ma50": 208.3618,
      "prevClose": 221.55,
      "avgVolume10": 5173751,
      "avgVolume20": 4321900,
      "changePercent": -4.42,
      "avgVolumeForScore": 4321900
    },
    "ma_cross": {
      "ma20": 213.411,
      "ma50": 208.3618,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 213.3185,
      "prevMa50": 207.7094,
      "spreadPct": 2.42,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 196.3531,
      "upper": 230.4689,
      "position": "中間"
    },
    "rsi_short": 27.04,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 1.23
    }
  }
}

{
  "close": 211.76,
  "volume": 5302507,
  "changePercent": -4.42
}